TXMD · TherapeuticsMD, Inc. · Fails to Deliver
$1.75
-0.07 (-3.85%)
At close · Nov 5
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5
7365
Avg daily vol (3M)
23.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.